Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment. (Core HTA 2)
Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment. (Core HTA 2)
Country | Agency | Status | Link | Details on adaptation process | Contact information |
---|---|---|---|---|---|
Croatia | AAZ | 2015 | Summary of information from the report for decision makers and website | Mirjana Huic (Mirjana.Huic@aaz.hr) | |
Spain | ISCII | 2016 | Summary of information from the report | Iñaki Imaz |